{"gene":"IGFBP2","run_date":"2026-06-10T01:55:22","timeline":{"discoveries":[{"year":2006,"finding":"IGFBP2 promotes cell mobility through direct interaction with integrin α5 via its RGD domain (D306). An RGD→RGE point mutant (D306E) abolished co-immunoprecipitation with integrin α5 and eliminated the elevation in cell migration, demonstrating that the RGD domain is essential for this interaction and its functional consequence.","method":"Co-immunoprecipitation, RGD-to-RGE site-directed mutagenesis, siRNA knockdown of integrin α5, migration assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1/2 / Strong — reciprocal Co-IP combined with active-site mutagenesis and siRNA rescue, multiple orthogonal methods in one study","pmids":["16569642"],"is_preprint":false},{"year":2014,"finding":"IGFBP2 stimulates osteoblast differentiation through its heparin-binding domain-1 (HBD-1), which interacts with receptor tyrosine phosphatase β (RPTPβ). Disruption of this interaction, overexpression of RPTPβ, or HBD-1 mutations all impaired AKT activation and differentiation; a synthetic HBD-1 peptide rescued differentiation in IGFBP-2-null calvarial osteoblasts.","method":"RPTPβ co-immunoprecipitation, HBD-1 domain mutagenesis, IGFBP-2 knockout osteoblast rescue, synthetic peptide addition, AKT activation assays","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods (mutagenesis, KO rescue, peptide rescue, interaction disruption) in one study","pmids":["24839202"],"is_preprint":false},{"year":2015,"finding":"IGFBP2 potentiates nuclear accumulation of EGFR and activates EGFR/STAT3 signaling, augmenting STAT3 transactivation. Both exogenous IGFBP2 treatment and cellular overexpression triggered aberrant EGFR activation and subsequent STAT3 signaling; nuclear IGFBP2 directly enhanced invasive and migratory capacities of glioblastoma cells.","method":"IGFBP2 overexpression and exogenous treatment, nuclear fractionation, STAT3 reporter assays, invasion/migration assays in glioblastoma cells","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional fractionation and multiple signaling readouts, single lab, no structural validation","pmids":["25893308"],"is_preprint":false},{"year":2011,"finding":"IGFBP2 promotes transcriptional activation of the VEGF gene promoter through nuclear localization. Transactivation of VEGF promoter occurred only in the presence of intracellular IGFBP2; cell fractionation and immunofluorescence confirmed nuclear localization. IGFBP2-overexpressing neuroblastoma xenografts induced neomicrovascularization in vivo.","method":"VEGF promoter luciferase reporter co-transfection, cell fractionation, immunofluorescence, chick embryo chorioallantoic membrane xenograft assay","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assay plus fractionation and in vivo angiogenesis assay, single lab","pmids":["21750048"],"is_preprint":false},{"year":2016,"finding":"IGFBP2 induces NF-κB-dependent epithelial-mesenchymal transition (EMT) in pancreatic ductal adenocarcinoma by triggering nuclear translocation and phosphorylation of p65 NF-κB through the PI3K/Akt/IKKβ pathway. Enforced PTEN expression blocked this cascade and restored epithelial phenotype.","method":"IGFBP2 overexpression/knockdown, nuclear fractionation for p65, pathway inhibitors, PTEN overexpression epistasis, invasion and metastasis assays in vitro and in vivo","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis (PTEN rescue) plus fractionation and multiple pathway readouts, single lab","pmids":["27659045"],"is_preprint":false},{"year":2018,"finding":"IGFBP2 interacts with integrin α5 and β1 subunits and enhances vasculogenic mimicry in glioma through a FAK/ERK-dependent pathway that activates transcription factor SP1, which binds the CD144 promoter to upregulate CD144 expression. MMP2 expression was also augmented.","method":"Co-immunoprecipitation (integrin α5/β1), luciferase reporter assay, ChIP assay (SP1 binding to CD144 promoter), FAK/ERK pathway inhibition, orthotopic mouse model with IGFBP2 knockdown","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — Co-IP, ChIP, reporter assay, and in vivo validation in one study with multiple orthogonal methods","pmids":["30368528"],"is_preprint":false},{"year":2008,"finding":"MMP-9 proteolyzes the IGFBP2-IGFII complex in vitro, releasing free IGFII that enhances motility and growth of astrocytoma cells. MMP-2 and MT1-MMP did not proteolyze this complex. Formation of the IGFBP2-IGFII complex also inhibited IGFBP2's own cell motility-promoting effect by reducing the pool of free IGFBP2.","method":"In vitro proteolysis assay with recombinant MMPs, cell motility and growth assays with liberated IGFII","journal":"Glia","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution assay with defined substrates and matched negative controls (MMP-2, MT1-MMP)","pmids":["18563800"],"is_preprint":false},{"year":2015,"finding":"IGF-I and IGFBP-2 coordinately stimulate osteoblast differentiation by inducing AMPK activation through their respective receptors (IGF-IR and RPTPβ). Early AMPK activation stimulates autophagy via ULK-1 S555 phosphorylation and beclin-1/LC3II induction, which is required for differentiation; subsequent AMPK down-regulation after day 9 allows mTOR/AKT induction to suppress autophagy and complete differentiation.","method":"AMPK inhibitors/constitutively active AMPK overexpression, receptor blocking, autophagy component analysis (ULK-1, beclin-1, LC3II), time-course differentiation assays in MC-3T3 and calvarial osteoblasts","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pathway components measured with gain/loss of function, single lab","pmids":["26556533"],"is_preprint":false},{"year":2019,"finding":"IGFBP2 activates STAT3 in PDAC cells to augment IL-10 expression and secretion, driving polarization of macrophages toward an immunosuppressive M2 phenotype, which in turn increases regulatory T-cell infiltration and impairs anti-tumor T-cell immunity in a mouse model.","method":"IGFBP2 overexpression/knockdown, STAT3 activation assays, IL-10 ELISA, macrophage polarization assays, mouse PDAC tumor model, flow cytometry","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro mechanistic dissection plus in vivo model, single lab","pmids":["33309859"],"is_preprint":false},{"year":2013,"finding":"IGFBP2 acting via integrin receptors reduces PTEN levels in breast epithelial cells, thereby promoting survival and protecting against chemotherapy-induced death. This IGFBP2-integrin-PTEN axis also upregulates estrogen receptor-α (ERα) mRNA and protein; silencing ERα blocked IGFBP2-conferred survival. Silencing IGFBP2 increased PTEN and sensitized cells to chemotherapy.","method":"siRNA knockdown of IGFBP2 and ERα, exogenous IGFBP2 treatment, integrin receptor blocking, PTEN western blotting, cell viability assays, PI3K inhibition","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple siRNA knockdowns and receptor blocking, orthogonal readouts, single lab","pmids":["23515291"],"is_preprint":false},{"year":2013,"finding":"IGFBP2 is causally associated with dasatinib resistance in NSCLC via focal adhesion kinase (FAK) activation. Ectopic overexpression or knockdown of IGFBP2 reversed the dasatinib susceptibility phenotype; FAK activation was associated with high IGFBP2 expression and partially mediated the resistance.","method":"Western blot/ELISA for IGFBP2 in 7 NSCLC lines, IGFBP2 overexpression/knockdown, cell viability assays, FAK inhibitor combination treatment in vitro and in vivo","journal":"Molecular cancer therapeutics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — causal relationship established by gain/loss of function with in vivo validation, single lab","pmids":["24130049"],"is_preprint":false},{"year":2019,"finding":"IGFBP2 protects esophageal adenocarcinoma cells from acidic bile salts-induced DNA double-strand breaks by promoting nuclear accumulation and phosphorylation of EGFR and DNA-PKcs. Co-immunoprecipitation demonstrated co-localization of IGFBP2 with EGFR and DNA-PKcs after acidic bile salts treatment. IGFBP2 also stabilized EGFR protein (cycloheximide chase assay).","method":"Co-immunoprecipitation, nuclear fractionation, cycloheximide chase assay, IGFBP2 overexpression/knockdown, DNA damage assays (γH2AX), apoptosis assays","journal":"Journal of experimental & clinical cancer research","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — Co-IP plus protein stability assay and nuclear fractionation with functional DNA damage readout, multiple orthogonal methods","pmids":["30626422"],"is_preprint":false},{"year":2020,"finding":"Intracellular IGFBP2 stabilizes cytoplasmic p21 by protecting it from ubiquitin-dependent degradation in psoriatic keratinocytes, thereby inhibiting apoptosis. Cytoplasmic p21 suppresses pro-caspase 3 cleavage and JNK phosphorylation. Abrogation of IGFBP2 or p21 restored apoptosis.","method":"IGFBP2 overexpression/knockdown in psoriatic keratinocytes, co-immunoprecipitation (IGFBP2-p21), ubiquitination assay, caspase-3 cleavage assay, JNK phosphorylation","journal":"Aging","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and functional rescue in primary patient-derived cells, single lab","pmids":["32302288"],"is_preprint":false},{"year":2020,"finding":"IGFBP2 regulates PD-L1 expression in melanoma by facilitating nuclear accumulation of EGFR and activating the EGFR/STAT3/PD-L1 signaling pathway. IGFBP2 knockdown reduced nuclear EGFR, STAT3 activation, and PD-L1 levels both in vitro and in vivo.","method":"IGFBP2 overexpression/knockdown, nuclear fractionation, EGFR/STAT3 phosphorylation assays, PD-L1 expression, in vivo xenograft model","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — fractionation and pathway analysis with in vivo confirmation, single lab","pmids":["32120023"],"is_preprint":false},{"year":2018,"finding":"IGFBP2 promotes EMT in salivary adenoid cystic carcinoma by enhancing NF-κB (p65) nuclear translocation, which then drives ZEB1 transcription. Mutation of the nuclear localization signal of IGFBP2 impeded p65 nuclear translocation, lowered ZEB1 expression, and abrogated the EMT process and metastasis in xenograft models.","method":"IGFBP2 nuclear localization signal mutant, nuclear fractionation, NF-κB reporter, ZEB1 expression analysis, EMT markers, xenograft metastasis models","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — NLS mutagenesis with fractionation and in vivo validation, single lab","pmids":["29885520"],"is_preprint":false},{"year":2019,"finding":"IGFBP2 upregulates ZEB1 in hepatocellular carcinoma via NF-κB signaling: IGFBP2 overexpression promotes nuclear localization of p65, which binds the ZEB1 promoter to drive transcription. Cell fractionation confirmed IGFBP2-induced p65 nuclear translocation.","method":"Dual-fluorescein reporter for NF-κB, cell fractionation for p65, IGFBP2 overexpression/knockdown, ZEB1/EMT marker measurement","journal":"Digestive and liver disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assay plus fractionation with functional phenotype, single lab","pmids":["31818638"],"is_preprint":false},{"year":2010,"finding":"IGFBP2 overexpression reverses diabetes (lowers blood glucose and insulin) in insulin-resistant and insulin-deficient mouse models without significantly reducing body weight. Hyperinsulinemic clamp studies showed a 3-fold improvement in hepatic insulin sensitivity following IGFBP2 adenoviral treatment in ob/ob mice, establishing IGFBP2 as a leptin-regulated mediator of glucose metabolism.","method":"Adenoviral IGFBP2 overexpression in ob/ob, Ay/a, diet-induced obese, and STZ-treated mice; hyperinsulinemic-euglycemic clamp studies; liver microarray","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo gain-of-function with metabolic clamp studies across multiple mouse models, multiple orthogonal readouts","pmids":["20074524"],"is_preprint":false},{"year":2016,"finding":"Methylation of a specific intronic CpG site (CpG2605) in the IGFBP2 gene suppresses its expression; in vitro selective methylation of CpG2605 reduced reporter activity by ~85%. This epigenetic inhibition of hepatic IGFBP2 occurs early in life (before obesity) and predicts later fatty liver development in mice.","method":"Combined bisulfite restriction analysis, luciferase reporter with selective CpG methylation, quantitative methylation-specific PCR, gene expression analysis","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — reporter assay with defined CpG methylation demonstrates functional impact, single lab","pmids":["27126637"],"is_preprint":false},{"year":2009,"finding":"p16(INK4a) is a negative regulator of IGFBP2 expression; loss of Ink4a-Arf in a mouse glioma model elevated endogenous tumor cell IGFBP2 and bypassed the requirement for exogenous IGFBP2 for glioma progression. An inverse relationship between p16(INK4a) and IGFBP2 was confirmed in human glioma tissues and 90 cancer cell lines.","method":"RCAS/Ntv-a transgenic mouse model, Ink4a-Arf null background epistasis, antisense IGFBP2 RCAS vector, Western blotting, reverse-phase protein lysate arrays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis in mouse model replicated in human tissue samples and cancer cell line panel","pmids":["19805356"],"is_preprint":false},{"year":2008,"finding":"IGFBP2 expression in the hippocampus is upregulated by estrogen in a brain region-specific manner (hippocampus but not hypothalamus) in ovariectomized rats. Time-dependent regulation in rat pituitary cell lines confirmed estrogen up-regulates IGFBP2 mRNA.","method":"Microarray analysis, quantitative RT-PCR in ovariectomized rat hippocampus and hypothalamus, cell line estrogen treatment","journal":"Endocrine journal","confidence":"Low","confidence_rationale":"Tier 3 / Weak — mRNA expression analysis only, no protein-level mechanistic follow-up","pmids":["18946176"],"is_preprint":false},{"year":2013,"finding":"IGFBP2 downregulation inhibits IGF1R phosphorylation and signaling; exogenous IGFBP2 potentiates IGF1R antibody activity against rhabdomyosarcoma cells and reverses acquired resistance to IGF1R antibody therapy in vivo. Selection against IGFBP2 expression represents a mechanism of acquired resistance to IGF1R-targeted therapy.","method":"In vivo IGF1R antibody-resistant model generation, IGFBP2 expression analysis, exogenous IGFBP2 addition, IGF1R phosphorylation assays, PI3K/mTOR inhibitor combinations","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo resistance model with exogenous rescue, IGF1R phosphorylation mechanistic readout, single lab","pmids":["24292683"],"is_preprint":false},{"year":2013,"finding":"Hyperglycemia increases IGFBP2 expression in prostate cancer cells by increasing histone H3 and H4 acetylation at the IGFBP2 gene promoter; siRNA silencing of IGFBP2 abolished the glucose-induced resistance to docetaxel-induced apoptosis.","method":"Chromatin immunoprecipitation (ChIP) for histone acetylation at IGFBP2 promoter, siRNA knockdown, IGFBP2 ELISA, cell death assays (Trypan Blue), bisulfite restriction analysis","journal":"Endocrine-related cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP linking epigenetic mark to IGFBP2 expression combined with functional siRNA rescue, single lab","pmids":["23959956"],"is_preprint":false},{"year":2019,"finding":"IGFBP2 is a downstream effector of P2Y1 receptor signaling in astrocytes that causes neuronal hyperexcitability. Genetic P2Y1R overexpression in astrocytes increased both astrocytic and neuronal Ca2+ signals; IGFBP2 was identified as the downstream molecule and acts as an excitatory signal causing neuronal excitation. In epilepsy and stroke models, reactive astrocytes upregulated P2Y1R and IGFBP2.","method":"Astrocyte-specific P2Y1R overexpression in mice, Ca2+ imaging, IGFBP2 identification as downstream mediator, neurological disease models (epilepsy, stroke)","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic overexpression with Ca2+ imaging and disease model validation, single lab","pmids":["39117630"],"is_preprint":false},{"year":2019,"finding":"IGFBP2 enhances excitatory synaptic inputs onto CA1 pyramidal neurons, facilitates intrinsic excitability and long-term potentiation (LTP) by enhancing NMDA receptor-dependent EPSCs, and promotes neurite proliferation and elongation. Knockout of igfbp2 reduces pyramidal cell and interneuron numbers, impairs LTP and cognitive performance; these deficits are rescued by exogenous IGFBP2.","method":"Igfbp2 knockout mice, electrophysiology (LTP, EPSC, excitability), NMDA receptor-dependent current measurements, behavioral cognition tests, exogenous IGFBP2 rescue","journal":"Advanced science","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — KO phenotype with electrophysiological mechanistic readouts and rescue experiments, multiple orthogonal methods","pmids":["31832311"],"is_preprint":false},{"year":2017,"finding":"IGFBP2 exerts anxiolytic/antidepressant effects in rat PTSD models via an IGF-1 receptor-independent mechanism. Unlike IGF-1, effects were not blocked by the IGF1R antagonist JB1 or AMPA receptor antagonist NBQX. IGFBP2 increased mature dendritic spine densities in medial prefrontal cortex and hippocampus 24 hours post-dosing, suggesting structural plasticity as a mechanism.","method":"Porsolt, contextual fear conditioning, and chronic unpredictable stress models; selective receptor antagonists (JB1, NBQX); dendritic spine morphology measurement in dentate gyrus and mPFC","journal":"The international journal of neuropsychopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological receptor antagonists establish IGF1R-independence; structural plasticity measurement, single lab with multiple behavioral models","pmids":["28158790"],"is_preprint":false},{"year":2022,"finding":"An IGFBP2-mimetic peptide (JB2) promotes synaptic plasticity via NMDA receptor activation, gene transcription/translation, and IGF2 receptors (not IGF1 receptor-dependent). JB2 directly binds to dendrites/synapses and induces remodeling of the membrane phosphoproteome; it rescued synaptic, cognitive, and behavioral deficits in a Shank3 haploinsufficiency mouse model.","method":"Peptide binding assay, pharmacological receptor antagonism (IGF1R), phosphoproteomics, electrophysiology (synaptic plasticity), behavioral testing in Shank3+/- mice","journal":"Molecular psychiatry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods (binding, phosphoproteomics, electrophysiology, in vivo rescue) in one study","pmids":["36481930"],"is_preprint":false},{"year":2023,"finding":"IGFBP2 secreted by mammary adipocytes limits breast cancer invasion through binding and sequestration of cancer-derived IGF-II (IGF2). IGF-II depletion by siRNA or neutralizing antibody abolished breast cancer invasion, establishing IGF-II autocrine signaling as the target of IGFBP2-mediated suppression.","method":"Patient-derived adipocyte conditioned medium, IGFBP2 loss-of-function, IGF-II siRNA knockdown, IGF-II neutralizing antibody, invasion assays","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 2 / Strong — two independent methods (siRNA and neutralizing antibody) to confirm IGF-II as the target, patient-derived cells, multiple orthogonal approaches","pmids":["37436978"],"is_preprint":false},{"year":2024,"finding":"IGFBP2 induces podocyte apoptosis in diabetic kidney disease by binding integrin α5 (ITGA5) on podocytes and activating FAK phosphorylation, which causes mitochondrial injury (membrane potential decrease, ROS production). ITGA5 knockdown or FAK inhibition attenuated podocyte apoptosis caused by high glucose or IGFBP2 overexpression.","method":"IGFBP2 overexpression/knockdown, ITGA5 knockdown, FAK inhibitor, mitochondrial membrane potential and ROS assays, apoptosis assays, STZ-induced DKD mouse model","journal":"Apoptosis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ITGA5/FAK epistasis confirmed by knockdown and inhibitor, in vivo model, single lab","pmids":["38796567"],"is_preprint":false},{"year":2023,"finding":"Loss of IGFBP2 mediates alveolar type 2 cell (AEC2) senescence. In aged human-IGFBP2 transgenic mice, IGFBP2 reduced senescence and SASP factors in AEC2 cells and ameliorated bleomycin-induced lung fibrosis. Intranasal recombinant IGFBP2 delivery protected aged mice from fibrosis.","method":"Human IGFBP2 transgenic mice, recombinant IGFBP2 intranasal delivery, bleomycin lung injury model, AEC2 senescence markers, SASP factor measurement","journal":"Cell reports. Medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transgenic overexpression and exogenous rescue in vivo with defined cellular readout, single lab","pmids":["36787736"],"is_preprint":false},{"year":2024,"finding":"An omentum-specific high IGFBP2-expressing stromal population (transitioning between mesothelial and mesenchymal states) inhibits adipose stem/progenitor cell (hASPC) adipogenesis through IGFBP2 secretion. Single-cell RNA-seq identified this population and functional experiments confirmed secreted IGFBP2 as the anti-adipogenic effector.","method":"Single-cell and bulk RNA-seq of >30 human adipose SVF samples, conditioned medium/co-culture experiments, IGFBP2 functional blocking, adipogenesis assays","journal":"Cell metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — single-cell identification combined with functional inhibition experiment, single lab, no mutagenesis","pmids":["38729152"],"is_preprint":false},{"year":2021,"finding":"In mice, Igfbp2 deficiency significantly impairs bariatric surgery-induced loss in adiposity and early improvement in insulin sensitivity (but not long-term glucose homeostasis), demonstrating that circulating IGFBP2 plays a causal role in the early metabolic improvements of bariatric surgery.","method":"Igfbp2 knockout mice, RYGB/BPD-DS/SG bariatric surgery models, insulin tolerance tests, adiposity measurements","journal":"Cell reports. Medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic loss-of-function (KO) with defined metabolic phenotype in surgical model, single lab","pmids":["33948578"],"is_preprint":false},{"year":2020,"finding":"IGFBP2 stabilizes cytoplasmic β-catenin (via TRIM33 induction that depletes nuclear β-catenin) and cytoplasmic β-catenin then binds the 3'UTR of Oct4 RNA, regulating Oct4 transcript levels and promoting stemness in glioma cells. IGFBP2 overexpression/treatment induces TRIM33, an E3 ubiquitin ligase that degrades nuclear β-catenin.","method":"IGFBP2 overexpression/treatment, shRNA knockdown of TRIM33/β-catenin, RNA immunoprecipitation (RNAIP) for β-catenin/Oct4 RNA interaction, luciferase reporter, nuclear/cytoplasmic fractionation, neurosphere assay","journal":"Journal of neuro-oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNAIP and reporter assay establish cytoplasmic β-catenin/Oct4 mRNA interaction, fractionation confirms compartment, single lab","pmids":["32803659"],"is_preprint":false},{"year":2005,"finding":"IGFBP2 overexpression in developing chick long bones inhibits IGF-I- and IGF-II-mediated chondrocyte proliferation and matrix synthesis in vitro and in vivo, establishing IGFBP2 as an inhibitor of IGF action in skeletal development. IGFBP2 excess shortens long bones by inhibiting chondrocyte proliferation without affecting chondrocyte maturation markers.","method":"RCAS retroviral IGFBP2 overexpression in chick wing skeletal elements, in vitro chondrocyte proliferation/matrix synthesis assays with IGF-I, IGF-II, and long-R3-IGF-I (IGFBP-resistant analog)","journal":"Bone","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — in vivo overexpression model combined with in vitro mechanism dissection using IGFBP-resistant IGF analog, multiple orthogonal methods","pmids":["16183342"],"is_preprint":false},{"year":2008,"finding":"IGFBP2 upregulates DNA-PKcs expression in astrocytoma cells in a time- and dose-dependent manner following exogenous IGFBP2 stimulation. IGF-1 had no effect on DNA-PKcs induction, suggesting an IGF-1-independent mechanism for IGFBP2-driven DNA repair.","method":"Exogenous IGFBP2 stimulation of astrocytoma cells, time- and dose-response western blot for DNA-PKcs, comparison with IGF-1 treatment","journal":"Journal of child neurology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single-method protein induction assay, no mechanistic dissection of pathway, single lab","pmids":["18952587"],"is_preprint":false},{"year":2023,"finding":"SARM1 in neurons promotes neuroinflammation and demyelination in experimental autoimmune encephalomyelitis by upregulating IGFBP2, which activates NF-κB signaling. SARM1 knockout reduced neuronal IGFBP2 levels; restoring NF-κB activation in SARM1 knockout EAE mice partially reversed the protective phenotype.","method":"SARM1 conditional KO in CNS (Nestin-CKO), RNA-seq, RT-PCR, immunostaining, NF-κB activation assay, NF-κB activator rescue experiment in SARM1-KO mice","journal":"Acta physiologica","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis (KO plus NF-κB rescue) with pathway confirmation, single lab","pmids":["37186158"],"is_preprint":false},{"year":2021,"finding":"HIF-1α transcriptionally drives IGFBP2 expression in Wilms tumor, and IGFBP2 in turn supports constitutive IGF1-AKT signaling. Deficiency of either HIF-1α or IGFBP2 significantly impaired tumor growth and nearly abrogated metastasis in xenograft models; pharmacologic HIF-1α inhibition (echinomycin nanoliposomes) suppressed the HIF-1α-IGFBP2 axis.","method":"HIF-1α and IGFBP2 shRNA knockdown in xenografted Wilms tumor, patient-derived xenograft models, echinomycin nanoliposome treatment, AKT phosphorylation assays","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis (HIF-1α KD → IGFBP2 → AKT) with pharmacologic confirmation in PDX model, single lab","pmids":["34155347"],"is_preprint":false}],"current_model":"IGFBP2 is a secreted and intracellular pleiotropic protein that (1) binds and sequesters IGF-I and IGF-II via its IGF-binding domain, modulating their availability and downstream IGF receptor signaling; (2) interacts with integrin α5 (and β1) via its C-terminal RGD motif to activate FAK/ERK/PI3K-AKT pathways, promoting cell migration, invasion, and survival while reducing PTEN; (3) translocates to the nucleus where it potentiates EGFR nuclear accumulation and EGFR/STAT3 transcriptional activation of target genes including VEGF and PD-L1; (4) activates NF-κB (p65 nuclear translocation) via PI3K/Akt/IKKβ to drive EMT and metastasis; (5) stimulates osteoblast differentiation through its heparin-binding domain-1 interacting with RPTPβ to activate AKT; (6) stabilizes cytoplasmic p21 to inhibit apoptosis; (7) acts as a leptin-regulated hepatokine that improves hepatic insulin sensitivity in vivo; and (8) in the brain, enhances NMDA receptor-dependent LTP and excitatory synaptic transmission, with IGF1R-independent mechanisms mediating neuroplasticity effects."},"narrative":{"mechanistic_narrative":"IGFBP2 is a secreted and intracellular pleiotropic protein that governs IGF availability and engages cell-surface and nuclear signaling to control cell migration, survival, differentiation, and metabolism [PMID:16569642, PMID:37436978, PMID:16183342]. Its canonical extracellular role is to bind and sequester IGF-II: adipocyte-derived IGFBP2 limits IGF-II autocrine signaling to suppress breast cancer invasion [PMID:37436978], and IGFBP2 excess inhibits IGF-I/IGF-II-driven chondrocyte proliferation during skeletal development [PMID:16183342]; the IGFBP2-IGF-II complex is cleaved by MMP-9 to liberate active IGF-II [PMID:18563800]. Beyond ligand sequestration, IGFBP2 acts as a signaling ligand through an RGD motif (D306) that binds integrin α5/β1, driving FAK/ERK and PI3K/Akt activation to promote migration, vasculogenic mimicry via SP1/CD144, survival through PTEN reduction, and—on podocytes—FAK-dependent mitochondrial injury and apoptosis [PMID:16569642, PMID:30368528, PMID:23515291, PMID:38796567]. A separate heparin-binding domain (HBD-1) engages RPTPβ to activate AKT and stimulate osteoblast differentiation [PMID:24839202]. IGFBP2 also translocates to the nucleus, where it potentiates EGFR nuclear accumulation and EGFR/STAT3 transactivation of targets including VEGF and PD-L1, and where it activates NF-κB (p65) through PI3K/Akt/IKKβ to drive ZEB1-dependent epithelial-mesenchymal transition and metastasis [PMID:25893308, PMID:21750048, PMID:32120023, PMID:29885520, PMID:31818638]. Through STAT3-driven IL-10, IGFBP2 also reshapes the tumor immune microenvironment toward M2 macrophage polarization [PMID:33309859]. In metabolism, IGFBP2 is a leptin-regulated hepatokine that improves hepatic insulin sensitivity and reverses hyperglycemia in vivo [PMID:20074524], and in the CNS it enhances NMDA receptor-dependent excitatory transmission, LTP, and structural plasticity through IGF1R-independent mechanisms [PMID:31832311, PMID:28158790, PMID:36481930]. Its expression is controlled by p16(INK4a), HIF-1α, promoter histone acetylation, and intronic CpG methylation [PMID:19805356, PMID:34155347, PMID:23959956, PMID:27126637].","teleology":[{"year":2006,"claim":"Established that IGFBP2 acts not merely as an IGF carrier but as an integrin ligand, defining the RGD motif as the structural basis for a direct cell-motility-promoting interaction.","evidence":"Co-IP, RGD-to-RGE (D306E) mutagenesis, integrin α5 siRNA, and migration assays","pmids":["16569642"],"confidence":"High","gaps":["Did not resolve downstream kinase cascade from integrin engagement","Did not address β1 subunit contribution"]},{"year":2008,"claim":"Showed that proteolysis of the IGFBP2-IGF-II complex by MMP-9 controls bioavailable IGF-II, connecting matrix remodeling to IGF release and tumor cell motility.","evidence":"In vitro proteolysis with recombinant MMPs (negative controls MMP-2, MT1-MMP) and motility/growth assays","pmids":["18563800"],"confidence":"High","gaps":["Cleavage sites not mapped","In vivo relevance of MMP-9 cleavage not established"]},{"year":2010,"claim":"Defined IGFBP2 as a leptin-regulated metabolic hepatokine, answering whether IGFBP2 has a systemic glucose-regulatory function distinct from IGF sequestration.","evidence":"Adenoviral IGFBP2 overexpression across multiple diabetic mouse models with hyperinsulinemic-euglycemic clamp","pmids":["20074524"],"confidence":"High","gaps":["Molecular receptor/effector for hepatic insulin sensitization not identified","Direct hepatocyte target undefined"]},{"year":2011,"claim":"Demonstrated that intracellular/nuclear IGFBP2 has a transcriptional function, transactivating the VEGF promoter and driving angiogenesis.","evidence":"VEGF promoter luciferase reporter, cell fractionation, immunofluorescence, and chick CAM xenograft","pmids":["21750048"],"confidence":"Medium","gaps":["DNA-binding partner mediating promoter activation not identified","Single lab, no structural validation"]},{"year":2014,"claim":"Identified a second receptor system—HBD-1 binding RPTPβ to activate AKT—explaining how IGFBP2 promotes osteoblast differentiation independently of the integrin/RGD axis.","evidence":"RPTPβ Co-IP, HBD-1 mutagenesis, IGFBP2-null osteoblast rescue, synthetic peptide rescue","pmids":["24839202"],"confidence":"High","gaps":["Structural basis of HBD-1/RPTPβ interaction unresolved","How RPTPβ engagement activates AKT not detailed"]},{"year":2015,"claim":"Linked nuclear IGFBP2 to oncogenic receptor signaling by showing it potentiates EGFR nuclear accumulation and EGFR/STAT3 transactivation to drive glioblastoma invasion.","evidence":"Overexpression/exogenous treatment, nuclear fractionation, STAT3 reporter, invasion assays","pmids":["25893308"],"confidence":"Medium","gaps":["Direct IGFBP2-EGFR binding mode not defined","Mechanism of EGFR nuclear import unknown"]},{"year":2016,"claim":"Defined a PI3K/Akt/IKKβ-NF-κB(p65) cascade by which IGFBP2 drives EMT, with PTEN as an opposing brake.","evidence":"Overexpression/knockdown, p65 fractionation, pathway inhibitors, PTEN rescue epistasis, in vivo metastasis","pmids":["27659045"],"confidence":"Medium","gaps":["Upstream receptor coupling IGFBP2 to PI3K not specified here","Single lab"]},{"year":2018,"claim":"Showed the integrin-FAK/ERK axis feeds SP1-driven CD144 transcription to enable vasculogenic mimicry, and that NLS-dependent nuclear p65 translocation drives ZEB1-mediated EMT and metastasis.","evidence":"Co-IP (α5/β1), ChIP (SP1-CD144), reporter assays, NLS mutagenesis, orthotopic and xenograft models","pmids":["30368528","29885520"],"confidence":"High","gaps":["Crosstalk between cytoplasmic integrin signaling and nuclear NF-κB function not unified","ZEB1 promoter occupancy by p65 mapped only in part"]},{"year":2019,"claim":"Extended nuclear EGFR signaling to immune evasion (PD-L1 via EGFR/STAT3) and immunosuppression (STAT3/IL-10-driven M2 macrophage polarization and Treg infiltration), and established CNS roles in neuronal excitability and synaptic potentiation.","evidence":"Knockdown with PD-L1/STAT3 readouts and xenografts; macrophage polarization with PDAC model; astrocytic P2Y1R overexpression with Ca2+ imaging; igfbp2-KO electrophysiology with rescue","pmids":["32120023","33309859","39117630","31832311","31818638"],"confidence":"High","gaps":["Receptor mediating CNS excitability effects of IGFBP2 not defined","Whether nuclear and immune mechanisms operate in the same cells unclear"]},{"year":2020,"claim":"Identified intracellular protein-stabilization roles—protecting cytoplasmic p21 from ubiquitination to block apoptosis, and stabilizing cytoplasmic β-catenin via TRIM33 to regulate Oct4 and stemness.","evidence":"Co-IP and ubiquitination assays in keratinocytes; RNAIP, fractionation, and neurosphere assays in glioma","pmids":["32302288","32803659"],"confidence":"Medium","gaps":["Direct binding interfaces (IGFBP2-p21) not mapped","How a secreted protein accesses cytoplasmic substrates not resolved"]},{"year":2022,"claim":"Mechanistically dissected the neuroplasticity activity using an IGFBP2-mimetic peptide, showing NMDA receptor- and IGF2R-dependent (IGF1R-independent) synaptic remodeling and rescue of Shank3 deficits.","evidence":"Peptide binding, IGF1R antagonism, phosphoproteomics, electrophysiology, behavior in Shank3+/- mice","pmids":["36481930"],"confidence":"High","gaps":["The functional receptor on dendrites not definitively identified","Endogenous full-length IGFBP2 vs mimetic peptide equivalence not established"]},{"year":2024,"claim":"Showed context-dependent IGF-sequestration outcomes: adipocyte IGFBP2 restrains tumor invasion by binding cancer-derived IGF-II, while podocyte integrin α5/FAK signaling makes IGFBP2 pro-apoptotic in diabetic kidney disease.","evidence":"Patient-derived adipocyte CM with IGF-II siRNA/neutralizing antibody and invasion assays; ITGA5 knockdown and FAK inhibition with mitochondrial/apoptosis readouts and STZ-DKD model","pmids":["37436978","38796567"],"confidence":"High","gaps":["Determinants of pro- vs anti-tumor IGFBP2 output not unified","Tissue factors switching IGFBP2 between sequestration and signaling unknown"]},{"year":null,"claim":"How IGFBP2 partitions among its mutually exclusive activities—extracellular IGF sequestration, integrin/RPTPβ signaling, and nuclear transcriptional functions—within a given cell, and what controls its nuclear import and access to cytoplasmic substrates, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model unifying ligand-binding, RGD, HBD-1, and NLS functions","Mechanism of nuclear translocation undefined","Receptor for IGF1R-independent CNS effects not identified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140313","term_label":"molecular sequestering activity","supporting_discovery_ids":[26,6,32]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1,9]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[3,2,14]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,1]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[16,26,29]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[3,2,14]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[12,31]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,5,27]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[16,30]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[4,14,35]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[23,25,22]}],"complexes":[],"partners":["ITGA5","ITGB1","PTPRB","EGFR","IGF2","CDKN1A","CTNNB1","DNAPK"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P18065","full_name":"Insulin-like growth factor-binding protein 2","aliases":[],"length_aa":325,"mass_kda":34.8,"function":"Multifunctional protein that plays a critical role in regulating the availability of IGFs such as IGF1 and IGF2 to their receptors and thereby regulates IGF-mediated cellular processes including proliferation, differentiation, and apoptosis in a cell-type specific manner (PubMed:18563800, PubMed:38796567). Functions coordinately with receptor protein tyrosine phosphatase beta/PTPRB and the IGF1 receptor to regulate IGF1-mediated signaling by stimulating the phosphorylation of PTEN leading to its inactivation and AKT1 activation (PubMed:22869525). Plays a positive role in cell migration via interaction with integrin alpha5/ITGA5 through an RGD motif (PubMed:16569642). Additionally, interaction with ITGA5/ITGB1 enhances the adhesion of endothelial progenitor cells to endothelial cells (PubMed:26076738). Upon mitochondrial damage, facilitates apoptosis with ITGA5 of podocytes, and then activates the phosphorylation of focal adhesion kinase (FAK)-mediated mitochondrial injury (PubMed:38796567)","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P18065/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/IGFBP2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/IGFBP2","total_profiled":1310},"omim":[{"mim_id":"618157","title":"ISOLATED GROWTH HORMONE DEFICIENCY, TYPE IV; IGHD4","url":"https://www.omim.org/entry/618157"},{"mim_id":"611767","title":"MICRO RNA 126; MIR126","url":"https://www.omim.org/entry/611767"},{"mim_id":"608772","title":"MIGRATION AND INVASION INHIBITORY PROTEIN; MIIP","url":"https://www.omim.org/entry/608772"},{"mim_id":"604705","title":"MER TYROSINE KINASE PROTOONCOGENE; MERTK","url":"https://www.omim.org/entry/604705"},{"mim_id":"601489","title":"INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN, ACID-LABILE SUBUNIT; IGFALS","url":"https://www.omim.org/entry/601489"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Endoplasmic reticulum","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"blood vessel","ntpm":1281.4},{"tissue":"pancreas","ntpm":901.3}],"url":"https://www.proteinatlas.org/search/IGFBP2"},"hgnc":{"alias_symbol":[],"prev_symbol":["IBP2"]},"alphafold":{"accession":"P18065","domains":[{"cath_id":"4.10.40.20","chopping":"46-132","consensus_level":"high","plddt":84.4166,"start":46,"end":132},{"cath_id":"4.10.800.10","chopping":"260-320","consensus_level":"medium","plddt":76.3446,"start":260,"end":320}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P18065","model_url":"https://alphafold.ebi.ac.uk/files/AF-P18065-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P18065-F1-predicted_aligned_error_v6.png","plddt_mean":66.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=IGFBP2","jax_strain_url":"https://www.jax.org/strain/search?query=IGFBP2"},"sequence":{"accession":"P18065","fasta_url":"https://rest.uniprot.org/uniprotkb/P18065.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P18065/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P18065"}},"corpus_meta":[{"pmid":"20074524","id":"PMC_20074524","title":"Antidiabetic effects of IGFBP2, a leptin-regulated gene.","date":"2010","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/20074524","citation_count":238,"is_preprint":false},{"pmid":"7683512","id":"PMC_7683512","title":"Clinical studies of IGFBP-2 by radioimmunoassay.","date":"1993","source":"Growth regulation","url":"https://pubmed.ncbi.nlm.nih.gov/7683512","citation_count":160,"is_preprint":false},{"pmid":"12414507","id":"PMC_12414507","title":"Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation.","date":"2002","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12414507","citation_count":149,"is_preprint":false},{"pmid":"31925333","id":"PMC_31925333","title":"IGFBP2: integrative hub of developmental and oncogenic signaling network.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/31925333","citation_count":115,"is_preprint":false},{"pmid":"16569642","id":"PMC_16569642","title":"An interaction between insulin-like growth factor-binding protein 2 (IGFBP2) and integrin alpha5 is essential for IGFBP2-induced cell mobility.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16569642","citation_count":106,"is_preprint":false},{"pmid":"25544066","id":"PMC_25544066","title":"IGFBP-2: The dark horse in metabolism and cancer.","date":"2014","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/25544066","citation_count":98,"is_preprint":false},{"pmid":"21750048","id":"PMC_21750048","title":"IGFBP-2 enhances VEGF gene promoter activity and consequent promotion of angiogenesis by neuroblastoma cells.","date":"2011","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21750048","citation_count":95,"is_preprint":false},{"pmid":"30368528","id":"PMC_30368528","title":"IGFBP2 promotes vasculogenic mimicry formation via regulating CD144 and MMP2 expression in glioma.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/30368528","citation_count":94,"is_preprint":false},{"pmid":"16183342","id":"PMC_16183342","title":"Role of IGFBP2, IGF-I and IGF-II in regulating long bone growth.","date":"2005","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/16183342","citation_count":94,"is_preprint":false},{"pmid":"27659045","id":"PMC_27659045","title":"IGFBP2 Activates the NF-κB Pathway to Drive Epithelial-Mesenchymal Transition and Invasive Character in Pancreatic Ductal Adenocarcinoma.","date":"2016","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27659045","citation_count":94,"is_preprint":false},{"pmid":"26556533","id":"PMC_26556533","title":"IGF-I and IGFBP-2 Stimulate AMPK Activation and Autophagy, Which Are Required for Osteoblast Differentiation.","date":"2015","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/26556533","citation_count":76,"is_preprint":false},{"pmid":"33309859","id":"PMC_33309859","title":"IGFBP2 promotes tumor progression by inducing alternative polarization of macrophages in pancreatic ductal adenocarcinoma through the STAT3 pathway.","date":"2020","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/33309859","citation_count":76,"is_preprint":false},{"pmid":"15790698","id":"PMC_15790698","title":"Significant expression of IGFBP2 in breast cancer compared with benign lesions.","date":"2005","source":"Journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15790698","citation_count":74,"is_preprint":false},{"pmid":"23959956","id":"PMC_23959956","title":"Hyperglycaemia-induced chemoresistance of prostate cancer cells due to IGFBP2.","date":"2013","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23959956","citation_count":73,"is_preprint":false},{"pmid":"25893308","id":"PMC_25893308","title":"IGFBP2 potentiates nuclear EGFR-STAT3 signaling.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25893308","citation_count":72,"is_preprint":false},{"pmid":"34117361","id":"PMC_34117361","title":"COL11A1 activates cancer-associated fibroblasts by modulating TGF-β3 through the NF-κB/IGFBP2 axis in ovarian cancer cells.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/34117361","citation_count":70,"is_preprint":false},{"pmid":"32120023","id":"PMC_32120023","title":"IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma.","date":"2020","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/32120023","citation_count":69,"is_preprint":false},{"pmid":"27487563","id":"PMC_27487563","title":"The miR-204-3p-targeted IGFBP2 pathway is involved in xanthohumol-induced glioma cell apoptotic death.","date":"2016","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27487563","citation_count":64,"is_preprint":false},{"pmid":"36787736","id":"PMC_36787736","title":"Loss of IGFBP2 mediates alveolar type 2 cell senescence and promotes lung fibrosis.","date":"2023","source":"Cell reports. Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36787736","citation_count":63,"is_preprint":false},{"pmid":"21339190","id":"PMC_21339190","title":"DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression.","date":"2011","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/21339190","citation_count":63,"is_preprint":false},{"pmid":"31824433","id":"PMC_31824433","title":"IGFBP-2 Signaling in the Brain: From Brain Development to Higher Order Brain Functions.","date":"2019","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/31824433","citation_count":62,"is_preprint":false},{"pmid":"29721393","id":"PMC_29721393","title":"Immune heterogeneity and clinicopathologic characterization of IGFBP2 in 2447 glioma samples.","date":"2018","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/29721393","citation_count":61,"is_preprint":false},{"pmid":"20515648","id":"PMC_20515648","title":"IGFBP2 promotes glioma tumor stem cell expansion and survival.","date":"2010","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/20515648","citation_count":60,"is_preprint":false},{"pmid":"18373644","id":"PMC_18373644","title":"IGFBP2 and IGFBP5 overexpression correlates with the lymph node metastasis in T1 breast carcinomas.","date":"2008","source":"The breast journal","url":"https://pubmed.ncbi.nlm.nih.gov/18373644","citation_count":55,"is_preprint":false},{"pmid":"24839202","id":"PMC_24839202","title":"IGFBP-2 directly stimulates osteoblast differentiation.","date":"2014","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/24839202","citation_count":54,"is_preprint":false},{"pmid":"24130049","id":"PMC_24130049","title":"IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells.","date":"2013","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/24130049","citation_count":54,"is_preprint":false},{"pmid":"23515291","id":"PMC_23515291","title":"Insulin-like growth factor binding protein 2 (IGFBP-2) promotes growth and survival of breast epithelial cells: novel regulation of the estrogen receptor.","date":"2013","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/23515291","citation_count":53,"is_preprint":false},{"pmid":"26522454","id":"PMC_26522454","title":"Physiology and pathophysiology of IGFBP-1 and IGFBP-2 - consensus and dissent on metabolic control and malignant potential.","date":"2015","source":"Best practice & research. Clinical endocrinology & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/26522454","citation_count":52,"is_preprint":false},{"pmid":"27126637","id":"PMC_27126637","title":"Early hypermethylation of hepatic Igfbp2 results in its reduced expression preceding fatty liver in mice.","date":"2016","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27126637","citation_count":52,"is_preprint":false},{"pmid":"37982669","id":"PMC_37982669","title":"Proteomic Analysis of the Senescence-Associated Secretory Phenotype: GDF-15, IGFBP-2, and Cystatin-C Are Associated With Multiple Aging Traits.","date":"2024","source":"The journals of gerontology. Series A, Biological sciences and medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37982669","citation_count":50,"is_preprint":false},{"pmid":"19805356","id":"PMC_19805356","title":"IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19805356","citation_count":49,"is_preprint":false},{"pmid":"33416173","id":"PMC_33416173","title":"IGFBP2 in cancer: Pathological role and clinical significance (Review).","date":"2020","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/33416173","citation_count":48,"is_preprint":false},{"pmid":"24515759","id":"PMC_24515759","title":"Loss of PTEN expression is associated with IGFBP2 expression, younger age, and late stage in triple-negative breast cancer.","date":"2014","source":"American journal of clinical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24515759","citation_count":46,"is_preprint":false},{"pmid":"31373442","id":"PMC_31373442","title":"Circulating IGFBP-2: a novel biomarker for incident dementia.","date":"2019","source":"Annals of clinical and translational neurology","url":"https://pubmed.ncbi.nlm.nih.gov/31373442","citation_count":45,"is_preprint":false},{"pmid":"9714057","id":"PMC_9714057","title":"IGFBP-2 expression in a human cell line is associated with increased IGFBP-3 proteolysis, decreased IGFBP-1 expression and increased tumorigenicity.","date":"1998","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9714057","citation_count":44,"is_preprint":false},{"pmid":"27125842","id":"PMC_27125842","title":"Glioma progression is mediated by an addiction to aberrant IGFBP2 expression and can be blocked using anti-IGFBP2 strategies.","date":"2016","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/27125842","citation_count":43,"is_preprint":false},{"pmid":"18946176","id":"PMC_18946176","title":"Identification of Igf2, Igfbp2 and Enpp2 as estrogen-responsive genes in rat hippocampus.","date":"2008","source":"Endocrine journal","url":"https://pubmed.ncbi.nlm.nih.gov/18946176","citation_count":42,"is_preprint":false},{"pmid":"16514194","id":"PMC_16514194","title":"The effects of IGF-I on bovine follicle development and IGFBP-2 expression are dose and stage dependent.","date":"2006","source":"Reproduction (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/16514194","citation_count":42,"is_preprint":false},{"pmid":"10912521","id":"PMC_10912521","title":"Effects of IGFBP-2 overexpression in vitro and in vivo.","date":"2000","source":"Pediatric nephrology (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/10912521","citation_count":40,"is_preprint":false},{"pmid":"37031362","id":"PMC_37031362","title":"High baseline tumor burden-associated macrophages promote an immunosuppressive microenvironment and reduce the efficacy of immune checkpoint inhibitors through the IGFBP2-STAT3-PD-L1 pathway.","date":"2023","source":"Cancer communications (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/37031362","citation_count":39,"is_preprint":false},{"pmid":"21899885","id":"PMC_21899885","title":"High expression of IGFBP2 is associated with chemoresistance in adult acute myeloid leukemia.","date":"2011","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/21899885","citation_count":36,"is_preprint":false},{"pmid":"11914022","id":"PMC_11914022","title":"Roles of insulin-like growth factor-I (IGF-I) and IGF-I binding protein-2 (IGFBP2) and -5 (IGFBP5) in developing chick limbs.","date":"2001","source":"Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/11914022","citation_count":36,"is_preprint":false},{"pmid":"36206311","id":"PMC_36206311","title":"Spatial Transcriptomic Analysis of Ovarian Cancer Precursors Reveals Reactivation of IGFBP2 during Pathogenesis.","date":"2022","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/36206311","citation_count":35,"is_preprint":false},{"pmid":"23583027","id":"PMC_23583027","title":"The role of insulin-like-growth factor binding protein 2 (IGFBP2) and phosphatase and tensin homologue (PTEN) in the regulation of myoblast differentiation and hypertrophy.","date":"2013","source":"Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/23583027","citation_count":35,"is_preprint":false},{"pmid":"33948578","id":"PMC_33948578","title":"IGFBP-2 partly mediates the early metabolic improvements caused by bariatric surgery.","date":"2021","source":"Cell reports. Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33948578","citation_count":35,"is_preprint":false},{"pmid":"30347220","id":"PMC_30347220","title":"IGFBP2 promotes neural stem cell maintenance and proliferation differentially associated with glioblastoma subtypes.","date":"2018","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/30347220","citation_count":34,"is_preprint":false},{"pmid":"20858761","id":"PMC_20858761","title":"Patched1 inhibits epidermal progenitor cell expansion and basal cell carcinoma formation by limiting Igfbp2 activity.","date":"2010","source":"Cancer prevention research (Philadelphia, Pa.)","url":"https://pubmed.ncbi.nlm.nih.gov/20858761","citation_count":33,"is_preprint":false},{"pmid":"9795362","id":"PMC_9795362","title":"Retinoic acid stimulates IGF binding protein (IGFBP)-6 and depresses IGFBP-2 and IGFBP-4 in SK-N-SH human neuroblastoma cells.","date":"1998","source":"The Journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/9795362","citation_count":33,"is_preprint":false},{"pmid":"38778379","id":"PMC_38778379","title":"Icaritin-curcumol activates CD8+ T cells through regulation of gut microbiota and the DNMT1/IGFBP2 axis to suppress the development of prostate cancer.","date":"2024","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/38778379","citation_count":32,"is_preprint":false},{"pmid":"20730703","id":"PMC_20730703","title":"Modulation of IGFBP2 mRNA expression in white adipose tissue upon aging and obesity.","date":"2010","source":"Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme","url":"https://pubmed.ncbi.nlm.nih.gov/20730703","citation_count":32,"is_preprint":false},{"pmid":"32532003","id":"PMC_32532003","title":"Physiological Disturbance in Fatty Liver Energy Metabolism Converges on IGFBP2 Abundance and Regulation in Mice and Men.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32532003","citation_count":31,"is_preprint":false},{"pmid":"8817688","id":"PMC_8817688","title":"Genetic ablation of IGFBP-2 suggests functional redundancy in the IGFBP family.","date":"1995","source":"Progress in growth factor research","url":"https://pubmed.ncbi.nlm.nih.gov/8817688","citation_count":31,"is_preprint":false},{"pmid":"26348138","id":"PMC_26348138","title":"Roles of miR-278-3p in IBP2 regulation and Bombyx mori cytoplasmic polyhedrosis virus replication.","date":"2015","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/26348138","citation_count":30,"is_preprint":false},{"pmid":"27852048","id":"PMC_27852048","title":"IGFBP2 expression predicts IDH-mutant glioma patient survival.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27852048","citation_count":30,"is_preprint":false},{"pmid":"25944386","id":"PMC_25944386","title":"Novel anti IGFBP2 single chain variable fragment inhibits glioma cell migration and invasion.","date":"2015","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25944386","citation_count":30,"is_preprint":false},{"pmid":"34628696","id":"PMC_34628696","title":"SNAIL2 contributes to tumorigenicity and chemotherapy resistance in pancreatic cancer by regulating IGFBP2.","date":"2021","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/34628696","citation_count":30,"is_preprint":false},{"pmid":"26230658","id":"PMC_26230658","title":"Igfbp2 Deletion in Ovariectomized Mice Enhances Energy Expenditure but Accelerates Bone Loss.","date":"2015","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/26230658","citation_count":30,"is_preprint":false},{"pmid":"31560714","id":"PMC_31560714","title":"IGFBP2 promotes immunosuppression associated with its mesenchymal induction and FcγRIIB phosphorylation in glioblastoma.","date":"2019","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/31560714","citation_count":29,"is_preprint":false},{"pmid":"8944682","id":"PMC_8944682","title":"Expression of IGFBP-2, -3, and -4 mRNA during differentiation of Caco-2 colon epithelial cells.","date":"1996","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/8944682","citation_count":29,"is_preprint":false},{"pmid":"27776273","id":"PMC_27776273","title":"IGFBP-2 and -3 co-ordinately regulate IGF1 induced matrix mineralisation of differentiating human dental pulp cells.","date":"2016","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/27776273","citation_count":29,"is_preprint":false},{"pmid":"32302288","id":"PMC_32302288","title":"Intracellular Insulin-like growth factor binding protein 2 (IGFBP2) contributes to the senescence of keratinocytes in psoriasis by stabilizing cytoplasmic p21.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/32302288","citation_count":29,"is_preprint":false},{"pmid":"37982173","id":"PMC_37982173","title":"Cancer-associated fibroblast-associated gene IGFBP2 promotes glioma progression through induction of M2 macrophage polarization.","date":"2023","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/37982173","citation_count":28,"is_preprint":false},{"pmid":"30626422","id":"PMC_30626422","title":"Activation of EGFR-DNA-PKcs pathway by IGFBP2 protects esophageal adenocarcinoma cells from acidic bile salts-induced DNA damage.","date":"2019","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/30626422","citation_count":28,"is_preprint":false},{"pmid":"30999686","id":"PMC_30999686","title":"MiR-34b-5p Mediates the Proliferation and Differentiation of Myoblasts by Targeting IGFBP2.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/30999686","citation_count":27,"is_preprint":false},{"pmid":"31758655","id":"PMC_31758655","title":"Silencing circular RNA VANGL1 inhibits progression of bladder cancer by regulating miR-1184/IGFBP2 axis.","date":"2019","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31758655","citation_count":27,"is_preprint":false},{"pmid":"31832311","id":"PMC_31832311","title":"IGFBP2 Plays an Essential Role in Cognitive Development during Early Life.","date":"2019","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/31832311","citation_count":27,"is_preprint":false},{"pmid":"35569697","id":"PMC_35569697","title":"Metastatic colorectal carcinoma-associated fibroblasts have immunosuppressive properties related to increased IGFBP2 expression.","date":"2022","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/35569697","citation_count":27,"is_preprint":false},{"pmid":"18563800","id":"PMC_18563800","title":"Matrix metalloproteinase-9 interplays with the IGFBP2-IGFII complex to promote cell growth and motility in astrocytomas.","date":"2008","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/18563800","citation_count":26,"is_preprint":false},{"pmid":"25277046","id":"PMC_25277046","title":"Targeted mass spectrometry analysis of the proteins IGF1, IGF2, IBP2, IBP3 and A2GL by blood protein precipitation.","date":"2014","source":"Journal of proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/25277046","citation_count":25,"is_preprint":false},{"pmid":"29706932","id":"PMC_29706932","title":"Potential Functions of IGFBP-2 for Ovarian Folliculogenesis and Steroidogenesis.","date":"2018","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/29706932","citation_count":25,"is_preprint":false},{"pmid":"17171534","id":"PMC_17171534","title":"Expression of IGFBP2 in gastric carcinoma and relationship with clinicopathologic parameters and cell proliferation.","date":"2006","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/17171534","citation_count":25,"is_preprint":false},{"pmid":"29885520","id":"PMC_29885520","title":"IGFBP2 promotes salivary adenoid cystic carcinoma metastasis by activating the NF-κB/ZEB1 signaling pathway.","date":"2018","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/29885520","citation_count":25,"is_preprint":false},{"pmid":"8832579","id":"PMC_8832579","title":"The unique endometrial expression and genomic organization of the porcine IGFBP-2 gene.","date":"1996","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/8832579","citation_count":25,"is_preprint":false},{"pmid":"31818638","id":"PMC_31818638","title":"IGFBP2 upregulates ZEB1 expression and promotes hepatocellular carcinoma progression through NF-κB signaling pathway.","date":"2019","source":"Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver","url":"https://pubmed.ncbi.nlm.nih.gov/31818638","citation_count":24,"is_preprint":false},{"pmid":"24292683","id":"PMC_24292683","title":"Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24292683","citation_count":24,"is_preprint":false},{"pmid":"28903396","id":"PMC_28903396","title":"IGFBP2 plays an important role in heat shock protein 27-mediated cancer progression and metastasis.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28903396","citation_count":24,"is_preprint":false},{"pmid":"31559898","id":"PMC_31559898","title":"BMSC-derived leptin and IGFBP2 promote erlotinib resistance in lung adenocarcinoma cells through IGF-1R activation in hypoxic environment.","date":"2019","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31559898","citation_count":24,"is_preprint":false},{"pmid":"29500455","id":"PMC_29500455","title":"Trichostatin A reverses the chemoresistance of lung cancer with high IGFBP2 expression through enhancing autophagy.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29500455","citation_count":24,"is_preprint":false},{"pmid":"38918360","id":"PMC_38918360","title":"IGFBP2/ITGA5 promotes gefitinib resistance via activating STAT3/CXCL1 axis in non-small cell lung cancer.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/38918360","citation_count":22,"is_preprint":false},{"pmid":"26317790","id":"PMC_26317790","title":"IGFBP2 modulates the chemoresistant phenotype in esophageal adenocarcinoma.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26317790","citation_count":22,"is_preprint":false},{"pmid":"30272281","id":"PMC_30272281","title":"Downregulation of CD147 induces malignant melanoma cell apoptosis via the regulation of IGFBP2 expression.","date":"2018","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30272281","citation_count":22,"is_preprint":false},{"pmid":"28158790","id":"PMC_28158790","title":"IGFBP2 Produces Rapid-Acting and Long-Lasting Effects in Rat Models of Posttraumatic Stress Disorder via a Novel Mechanism Associated with Structural Plasticity.","date":"2017","source":"The international journal of neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28158790","citation_count":22,"is_preprint":false},{"pmid":"39117630","id":"PMC_39117630","title":"Disease-relevant upregulation of P2Y1 receptor in astrocytes enhances neuronal excitability via IGFBP2.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39117630","citation_count":21,"is_preprint":false},{"pmid":"32380764","id":"PMC_32380764","title":"Associations between IGF1, IGFBP2 and TGFß3 Genes Polymorphisms and Growth Performance of Broiler Chicken Lines.","date":"2020","source":"Animals : an open access journal from MDPI","url":"https://pubmed.ncbi.nlm.nih.gov/32380764","citation_count":21,"is_preprint":false},{"pmid":"38729152","id":"PMC_38729152","title":"A human omentum-specific mesothelial-like stromal population inhibits adipogenesis through IGFBP2 secretion.","date":"2024","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/38729152","citation_count":19,"is_preprint":false},{"pmid":"21924226","id":"PMC_21924226","title":"High IGFBP2 expression correlates with tumor severity in pediatric rhabdomyosarcoma.","date":"2011","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21924226","citation_count":19,"is_preprint":false},{"pmid":"31934083","id":"PMC_31934083","title":"IGFBP2 promotes the EMT of colorectal cancer cells by regulating E-cadherin expression.","date":"2019","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31934083","citation_count":19,"is_preprint":false},{"pmid":"28977895","id":"PMC_28977895","title":"Silencing IGFBP-2 decreases pancreatic cancer metastasis and enhances chemotherapeutic sensitivity.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28977895","citation_count":19,"is_preprint":false},{"pmid":"34155347","id":"PMC_34155347","title":"Targeting the HIF-1α-IGFBP2 axis therapeutically reduces IGF1-AKT signaling and blocks the growth and metastasis of relapsed anaplastic Wilms tumor.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/34155347","citation_count":18,"is_preprint":false},{"pmid":"30564296","id":"PMC_30564296","title":"IGFBP2 is a potential biomarker in acute kidney injury (AKI) and resveratrol-loaded nanoparticles prevent AKI.","date":"2018","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/30564296","citation_count":18,"is_preprint":false},{"pmid":"38796567","id":"PMC_38796567","title":"IGFBP2 induces podocyte apoptosis promoted by mitochondrial damage via integrin α5/FAK in diabetic kidney disease.","date":"2024","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/38796567","citation_count":17,"is_preprint":false},{"pmid":"32803659","id":"PMC_32803659","title":"Regulation of β-catenin by IGFBP2 and its cytoplasmic actions in glioma.","date":"2020","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32803659","citation_count":17,"is_preprint":false},{"pmid":"36104215","id":"PMC_36104215","title":"Gold Nanoparticles Disrupt the IGFBP2/mTOR/PTEN Axis to Inhibit Ovarian Cancer Growth.","date":"2022","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/36104215","citation_count":17,"is_preprint":false},{"pmid":"37436978","id":"PMC_37436978","title":"IGFBP2 secretion by mammary adipocytes limits breast cancer invasion.","date":"2023","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/37436978","citation_count":17,"is_preprint":false},{"pmid":"32168373","id":"PMC_32168373","title":"Estrogen Stimulation of Pleiotrophin Enhances Osteoblast Differentiation and Maintains Bone Mass in IGFBP-2 Null Mice.","date":"2020","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/32168373","citation_count":17,"is_preprint":false},{"pmid":"18952587","id":"PMC_18952587","title":"IGFBP2 is overexpressed by pediatric malignant astrocytomas and induces the repair enzyme DNA-PK.","date":"2008","source":"Journal of child neurology","url":"https://pubmed.ncbi.nlm.nih.gov/18952587","citation_count":17,"is_preprint":false},{"pmid":"37186158","id":"PMC_37186158","title":"SARM1 promotes the neuroinflammation and demyelination through IGFBP2/NF-κB pathway in experimental autoimmune encephalomyelitis mice.","date":"2023","source":"Acta physiologica (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/37186158","citation_count":16,"is_preprint":false},{"pmid":"36481930","id":"PMC_36481930","title":"An IGFBP2-derived peptide promotes neuroplasticity and rescues deficits in a mouse model of Phelan-McDermid syndrome.","date":"2022","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/36481930","citation_count":16,"is_preprint":false},{"pmid":"32279122","id":"PMC_32279122","title":"Astrocytic IGFBP2 and CHI3L1 in cerebrospinal fluid drive cortical metastasis of HER2+breast cancer.","date":"2020","source":"Clinical & experimental metastasis","url":"https://pubmed.ncbi.nlm.nih.gov/32279122","citation_count":16,"is_preprint":false},{"pmid":"36430152","id":"PMC_36430152","title":"circSMARCA5 Is an Upstream Regulator of the Expression of miR-126-3p, miR-515-5p, and Their mRNA Targets, Insulin-like Growth Factor Binding Protein 2 (IGFBP2) and NRAS Proto-Oncogene, GTPase (NRAS) in Glioblastoma.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36430152","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":55452,"output_tokens":9580,"usd":0.155028,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19844,"output_tokens":4571,"usd":0.106747,"stage2_stop_reason":"end_turn"},"total_usd":0.261775,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2006,\n      \"finding\": \"IGFBP2 promotes cell mobility through direct interaction with integrin α5 via its RGD domain (D306). An RGD→RGE point mutant (D306E) abolished co-immunoprecipitation with integrin α5 and eliminated the elevation in cell migration, demonstrating that the RGD domain is essential for this interaction and its functional consequence.\",\n      \"method\": \"Co-immunoprecipitation, RGD-to-RGE site-directed mutagenesis, siRNA knockdown of integrin α5, migration assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1/2 / Strong — reciprocal Co-IP combined with active-site mutagenesis and siRNA rescue, multiple orthogonal methods in one study\",\n      \"pmids\": [\"16569642\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"IGFBP2 stimulates osteoblast differentiation through its heparin-binding domain-1 (HBD-1), which interacts with receptor tyrosine phosphatase β (RPTPβ). Disruption of this interaction, overexpression of RPTPβ, or HBD-1 mutations all impaired AKT activation and differentiation; a synthetic HBD-1 peptide rescued differentiation in IGFBP-2-null calvarial osteoblasts.\",\n      \"method\": \"RPTPβ co-immunoprecipitation, HBD-1 domain mutagenesis, IGFBP-2 knockout osteoblast rescue, synthetic peptide addition, AKT activation assays\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods (mutagenesis, KO rescue, peptide rescue, interaction disruption) in one study\",\n      \"pmids\": [\"24839202\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"IGFBP2 potentiates nuclear accumulation of EGFR and activates EGFR/STAT3 signaling, augmenting STAT3 transactivation. Both exogenous IGFBP2 treatment and cellular overexpression triggered aberrant EGFR activation and subsequent STAT3 signaling; nuclear IGFBP2 directly enhanced invasive and migratory capacities of glioblastoma cells.\",\n      \"method\": \"IGFBP2 overexpression and exogenous treatment, nuclear fractionation, STAT3 reporter assays, invasion/migration assays in glioblastoma cells\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional fractionation and multiple signaling readouts, single lab, no structural validation\",\n      \"pmids\": [\"25893308\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"IGFBP2 promotes transcriptional activation of the VEGF gene promoter through nuclear localization. Transactivation of VEGF promoter occurred only in the presence of intracellular IGFBP2; cell fractionation and immunofluorescence confirmed nuclear localization. IGFBP2-overexpressing neuroblastoma xenografts induced neomicrovascularization in vivo.\",\n      \"method\": \"VEGF promoter luciferase reporter co-transfection, cell fractionation, immunofluorescence, chick embryo chorioallantoic membrane xenograft assay\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assay plus fractionation and in vivo angiogenesis assay, single lab\",\n      \"pmids\": [\"21750048\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"IGFBP2 induces NF-κB-dependent epithelial-mesenchymal transition (EMT) in pancreatic ductal adenocarcinoma by triggering nuclear translocation and phosphorylation of p65 NF-κB through the PI3K/Akt/IKKβ pathway. Enforced PTEN expression blocked this cascade and restored epithelial phenotype.\",\n      \"method\": \"IGFBP2 overexpression/knockdown, nuclear fractionation for p65, pathway inhibitors, PTEN overexpression epistasis, invasion and metastasis assays in vitro and in vivo\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis (PTEN rescue) plus fractionation and multiple pathway readouts, single lab\",\n      \"pmids\": [\"27659045\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"IGFBP2 interacts with integrin α5 and β1 subunits and enhances vasculogenic mimicry in glioma through a FAK/ERK-dependent pathway that activates transcription factor SP1, which binds the CD144 promoter to upregulate CD144 expression. MMP2 expression was also augmented.\",\n      \"method\": \"Co-immunoprecipitation (integrin α5/β1), luciferase reporter assay, ChIP assay (SP1 binding to CD144 promoter), FAK/ERK pathway inhibition, orthotopic mouse model with IGFBP2 knockdown\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — Co-IP, ChIP, reporter assay, and in vivo validation in one study with multiple orthogonal methods\",\n      \"pmids\": [\"30368528\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"MMP-9 proteolyzes the IGFBP2-IGFII complex in vitro, releasing free IGFII that enhances motility and growth of astrocytoma cells. MMP-2 and MT1-MMP did not proteolyze this complex. Formation of the IGFBP2-IGFII complex also inhibited IGFBP2's own cell motility-promoting effect by reducing the pool of free IGFBP2.\",\n      \"method\": \"In vitro proteolysis assay with recombinant MMPs, cell motility and growth assays with liberated IGFII\",\n      \"journal\": \"Glia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution assay with defined substrates and matched negative controls (MMP-2, MT1-MMP)\",\n      \"pmids\": [\"18563800\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"IGF-I and IGFBP-2 coordinately stimulate osteoblast differentiation by inducing AMPK activation through their respective receptors (IGF-IR and RPTPβ). Early AMPK activation stimulates autophagy via ULK-1 S555 phosphorylation and beclin-1/LC3II induction, which is required for differentiation; subsequent AMPK down-regulation after day 9 allows mTOR/AKT induction to suppress autophagy and complete differentiation.\",\n      \"method\": \"AMPK inhibitors/constitutively active AMPK overexpression, receptor blocking, autophagy component analysis (ULK-1, beclin-1, LC3II), time-course differentiation assays in MC-3T3 and calvarial osteoblasts\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pathway components measured with gain/loss of function, single lab\",\n      \"pmids\": [\"26556533\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"IGFBP2 activates STAT3 in PDAC cells to augment IL-10 expression and secretion, driving polarization of macrophages toward an immunosuppressive M2 phenotype, which in turn increases regulatory T-cell infiltration and impairs anti-tumor T-cell immunity in a mouse model.\",\n      \"method\": \"IGFBP2 overexpression/knockdown, STAT3 activation assays, IL-10 ELISA, macrophage polarization assays, mouse PDAC tumor model, flow cytometry\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro mechanistic dissection plus in vivo model, single lab\",\n      \"pmids\": [\"33309859\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"IGFBP2 acting via integrin receptors reduces PTEN levels in breast epithelial cells, thereby promoting survival and protecting against chemotherapy-induced death. This IGFBP2-integrin-PTEN axis also upregulates estrogen receptor-α (ERα) mRNA and protein; silencing ERα blocked IGFBP2-conferred survival. Silencing IGFBP2 increased PTEN and sensitized cells to chemotherapy.\",\n      \"method\": \"siRNA knockdown of IGFBP2 and ERα, exogenous IGFBP2 treatment, integrin receptor blocking, PTEN western blotting, cell viability assays, PI3K inhibition\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple siRNA knockdowns and receptor blocking, orthogonal readouts, single lab\",\n      \"pmids\": [\"23515291\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"IGFBP2 is causally associated with dasatinib resistance in NSCLC via focal adhesion kinase (FAK) activation. Ectopic overexpression or knockdown of IGFBP2 reversed the dasatinib susceptibility phenotype; FAK activation was associated with high IGFBP2 expression and partially mediated the resistance.\",\n      \"method\": \"Western blot/ELISA for IGFBP2 in 7 NSCLC lines, IGFBP2 overexpression/knockdown, cell viability assays, FAK inhibitor combination treatment in vitro and in vivo\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — causal relationship established by gain/loss of function with in vivo validation, single lab\",\n      \"pmids\": [\"24130049\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"IGFBP2 protects esophageal adenocarcinoma cells from acidic bile salts-induced DNA double-strand breaks by promoting nuclear accumulation and phosphorylation of EGFR and DNA-PKcs. Co-immunoprecipitation demonstrated co-localization of IGFBP2 with EGFR and DNA-PKcs after acidic bile salts treatment. IGFBP2 also stabilized EGFR protein (cycloheximide chase assay).\",\n      \"method\": \"Co-immunoprecipitation, nuclear fractionation, cycloheximide chase assay, IGFBP2 overexpression/knockdown, DNA damage assays (γH2AX), apoptosis assays\",\n      \"journal\": \"Journal of experimental & clinical cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — Co-IP plus protein stability assay and nuclear fractionation with functional DNA damage readout, multiple orthogonal methods\",\n      \"pmids\": [\"30626422\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Intracellular IGFBP2 stabilizes cytoplasmic p21 by protecting it from ubiquitin-dependent degradation in psoriatic keratinocytes, thereby inhibiting apoptosis. Cytoplasmic p21 suppresses pro-caspase 3 cleavage and JNK phosphorylation. Abrogation of IGFBP2 or p21 restored apoptosis.\",\n      \"method\": \"IGFBP2 overexpression/knockdown in psoriatic keratinocytes, co-immunoprecipitation (IGFBP2-p21), ubiquitination assay, caspase-3 cleavage assay, JNK phosphorylation\",\n      \"journal\": \"Aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and functional rescue in primary patient-derived cells, single lab\",\n      \"pmids\": [\"32302288\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"IGFBP2 regulates PD-L1 expression in melanoma by facilitating nuclear accumulation of EGFR and activating the EGFR/STAT3/PD-L1 signaling pathway. IGFBP2 knockdown reduced nuclear EGFR, STAT3 activation, and PD-L1 levels both in vitro and in vivo.\",\n      \"method\": \"IGFBP2 overexpression/knockdown, nuclear fractionation, EGFR/STAT3 phosphorylation assays, PD-L1 expression, in vivo xenograft model\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — fractionation and pathway analysis with in vivo confirmation, single lab\",\n      \"pmids\": [\"32120023\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"IGFBP2 promotes EMT in salivary adenoid cystic carcinoma by enhancing NF-κB (p65) nuclear translocation, which then drives ZEB1 transcription. Mutation of the nuclear localization signal of IGFBP2 impeded p65 nuclear translocation, lowered ZEB1 expression, and abrogated the EMT process and metastasis in xenograft models.\",\n      \"method\": \"IGFBP2 nuclear localization signal mutant, nuclear fractionation, NF-κB reporter, ZEB1 expression analysis, EMT markers, xenograft metastasis models\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — NLS mutagenesis with fractionation and in vivo validation, single lab\",\n      \"pmids\": [\"29885520\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"IGFBP2 upregulates ZEB1 in hepatocellular carcinoma via NF-κB signaling: IGFBP2 overexpression promotes nuclear localization of p65, which binds the ZEB1 promoter to drive transcription. Cell fractionation confirmed IGFBP2-induced p65 nuclear translocation.\",\n      \"method\": \"Dual-fluorescein reporter for NF-κB, cell fractionation for p65, IGFBP2 overexpression/knockdown, ZEB1/EMT marker measurement\",\n      \"journal\": \"Digestive and liver disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assay plus fractionation with functional phenotype, single lab\",\n      \"pmids\": [\"31818638\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"IGFBP2 overexpression reverses diabetes (lowers blood glucose and insulin) in insulin-resistant and insulin-deficient mouse models without significantly reducing body weight. Hyperinsulinemic clamp studies showed a 3-fold improvement in hepatic insulin sensitivity following IGFBP2 adenoviral treatment in ob/ob mice, establishing IGFBP2 as a leptin-regulated mediator of glucose metabolism.\",\n      \"method\": \"Adenoviral IGFBP2 overexpression in ob/ob, Ay/a, diet-induced obese, and STZ-treated mice; hyperinsulinemic-euglycemic clamp studies; liver microarray\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo gain-of-function with metabolic clamp studies across multiple mouse models, multiple orthogonal readouts\",\n      \"pmids\": [\"20074524\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Methylation of a specific intronic CpG site (CpG2605) in the IGFBP2 gene suppresses its expression; in vitro selective methylation of CpG2605 reduced reporter activity by ~85%. This epigenetic inhibition of hepatic IGFBP2 occurs early in life (before obesity) and predicts later fatty liver development in mice.\",\n      \"method\": \"Combined bisulfite restriction analysis, luciferase reporter with selective CpG methylation, quantitative methylation-specific PCR, gene expression analysis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — reporter assay with defined CpG methylation demonstrates functional impact, single lab\",\n      \"pmids\": [\"27126637\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"p16(INK4a) is a negative regulator of IGFBP2 expression; loss of Ink4a-Arf in a mouse glioma model elevated endogenous tumor cell IGFBP2 and bypassed the requirement for exogenous IGFBP2 for glioma progression. An inverse relationship between p16(INK4a) and IGFBP2 was confirmed in human glioma tissues and 90 cancer cell lines.\",\n      \"method\": \"RCAS/Ntv-a transgenic mouse model, Ink4a-Arf null background epistasis, antisense IGFBP2 RCAS vector, Western blotting, reverse-phase protein lysate arrays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis in mouse model replicated in human tissue samples and cancer cell line panel\",\n      \"pmids\": [\"19805356\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"IGFBP2 expression in the hippocampus is upregulated by estrogen in a brain region-specific manner (hippocampus but not hypothalamus) in ovariectomized rats. Time-dependent regulation in rat pituitary cell lines confirmed estrogen up-regulates IGFBP2 mRNA.\",\n      \"method\": \"Microarray analysis, quantitative RT-PCR in ovariectomized rat hippocampus and hypothalamus, cell line estrogen treatment\",\n      \"journal\": \"Endocrine journal\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — mRNA expression analysis only, no protein-level mechanistic follow-up\",\n      \"pmids\": [\"18946176\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"IGFBP2 downregulation inhibits IGF1R phosphorylation and signaling; exogenous IGFBP2 potentiates IGF1R antibody activity against rhabdomyosarcoma cells and reverses acquired resistance to IGF1R antibody therapy in vivo. Selection against IGFBP2 expression represents a mechanism of acquired resistance to IGF1R-targeted therapy.\",\n      \"method\": \"In vivo IGF1R antibody-resistant model generation, IGFBP2 expression analysis, exogenous IGFBP2 addition, IGF1R phosphorylation assays, PI3K/mTOR inhibitor combinations\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo resistance model with exogenous rescue, IGF1R phosphorylation mechanistic readout, single lab\",\n      \"pmids\": [\"24292683\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Hyperglycemia increases IGFBP2 expression in prostate cancer cells by increasing histone H3 and H4 acetylation at the IGFBP2 gene promoter; siRNA silencing of IGFBP2 abolished the glucose-induced resistance to docetaxel-induced apoptosis.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP) for histone acetylation at IGFBP2 promoter, siRNA knockdown, IGFBP2 ELISA, cell death assays (Trypan Blue), bisulfite restriction analysis\",\n      \"journal\": \"Endocrine-related cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP linking epigenetic mark to IGFBP2 expression combined with functional siRNA rescue, single lab\",\n      \"pmids\": [\"23959956\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"IGFBP2 is a downstream effector of P2Y1 receptor signaling in astrocytes that causes neuronal hyperexcitability. Genetic P2Y1R overexpression in astrocytes increased both astrocytic and neuronal Ca2+ signals; IGFBP2 was identified as the downstream molecule and acts as an excitatory signal causing neuronal excitation. In epilepsy and stroke models, reactive astrocytes upregulated P2Y1R and IGFBP2.\",\n      \"method\": \"Astrocyte-specific P2Y1R overexpression in mice, Ca2+ imaging, IGFBP2 identification as downstream mediator, neurological disease models (epilepsy, stroke)\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic overexpression with Ca2+ imaging and disease model validation, single lab\",\n      \"pmids\": [\"39117630\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"IGFBP2 enhances excitatory synaptic inputs onto CA1 pyramidal neurons, facilitates intrinsic excitability and long-term potentiation (LTP) by enhancing NMDA receptor-dependent EPSCs, and promotes neurite proliferation and elongation. Knockout of igfbp2 reduces pyramidal cell and interneuron numbers, impairs LTP and cognitive performance; these deficits are rescued by exogenous IGFBP2.\",\n      \"method\": \"Igfbp2 knockout mice, electrophysiology (LTP, EPSC, excitability), NMDA receptor-dependent current measurements, behavioral cognition tests, exogenous IGFBP2 rescue\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — KO phenotype with electrophysiological mechanistic readouts and rescue experiments, multiple orthogonal methods\",\n      \"pmids\": [\"31832311\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"IGFBP2 exerts anxiolytic/antidepressant effects in rat PTSD models via an IGF-1 receptor-independent mechanism. Unlike IGF-1, effects were not blocked by the IGF1R antagonist JB1 or AMPA receptor antagonist NBQX. IGFBP2 increased mature dendritic spine densities in medial prefrontal cortex and hippocampus 24 hours post-dosing, suggesting structural plasticity as a mechanism.\",\n      \"method\": \"Porsolt, contextual fear conditioning, and chronic unpredictable stress models; selective receptor antagonists (JB1, NBQX); dendritic spine morphology measurement in dentate gyrus and mPFC\",\n      \"journal\": \"The international journal of neuropsychopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological receptor antagonists establish IGF1R-independence; structural plasticity measurement, single lab with multiple behavioral models\",\n      \"pmids\": [\"28158790\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"An IGFBP2-mimetic peptide (JB2) promotes synaptic plasticity via NMDA receptor activation, gene transcription/translation, and IGF2 receptors (not IGF1 receptor-dependent). JB2 directly binds to dendrites/synapses and induces remodeling of the membrane phosphoproteome; it rescued synaptic, cognitive, and behavioral deficits in a Shank3 haploinsufficiency mouse model.\",\n      \"method\": \"Peptide binding assay, pharmacological receptor antagonism (IGF1R), phosphoproteomics, electrophysiology (synaptic plasticity), behavioral testing in Shank3+/- mice\",\n      \"journal\": \"Molecular psychiatry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods (binding, phosphoproteomics, electrophysiology, in vivo rescue) in one study\",\n      \"pmids\": [\"36481930\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"IGFBP2 secreted by mammary adipocytes limits breast cancer invasion through binding and sequestration of cancer-derived IGF-II (IGF2). IGF-II depletion by siRNA or neutralizing antibody abolished breast cancer invasion, establishing IGF-II autocrine signaling as the target of IGFBP2-mediated suppression.\",\n      \"method\": \"Patient-derived adipocyte conditioned medium, IGFBP2 loss-of-function, IGF-II siRNA knockdown, IGF-II neutralizing antibody, invasion assays\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two independent methods (siRNA and neutralizing antibody) to confirm IGF-II as the target, patient-derived cells, multiple orthogonal approaches\",\n      \"pmids\": [\"37436978\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"IGFBP2 induces podocyte apoptosis in diabetic kidney disease by binding integrin α5 (ITGA5) on podocytes and activating FAK phosphorylation, which causes mitochondrial injury (membrane potential decrease, ROS production). ITGA5 knockdown or FAK inhibition attenuated podocyte apoptosis caused by high glucose or IGFBP2 overexpression.\",\n      \"method\": \"IGFBP2 overexpression/knockdown, ITGA5 knockdown, FAK inhibitor, mitochondrial membrane potential and ROS assays, apoptosis assays, STZ-induced DKD mouse model\",\n      \"journal\": \"Apoptosis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ITGA5/FAK epistasis confirmed by knockdown and inhibitor, in vivo model, single lab\",\n      \"pmids\": [\"38796567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Loss of IGFBP2 mediates alveolar type 2 cell (AEC2) senescence. In aged human-IGFBP2 transgenic mice, IGFBP2 reduced senescence and SASP factors in AEC2 cells and ameliorated bleomycin-induced lung fibrosis. Intranasal recombinant IGFBP2 delivery protected aged mice from fibrosis.\",\n      \"method\": \"Human IGFBP2 transgenic mice, recombinant IGFBP2 intranasal delivery, bleomycin lung injury model, AEC2 senescence markers, SASP factor measurement\",\n      \"journal\": \"Cell reports. Medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transgenic overexpression and exogenous rescue in vivo with defined cellular readout, single lab\",\n      \"pmids\": [\"36787736\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"An omentum-specific high IGFBP2-expressing stromal population (transitioning between mesothelial and mesenchymal states) inhibits adipose stem/progenitor cell (hASPC) adipogenesis through IGFBP2 secretion. Single-cell RNA-seq identified this population and functional experiments confirmed secreted IGFBP2 as the anti-adipogenic effector.\",\n      \"method\": \"Single-cell and bulk RNA-seq of >30 human adipose SVF samples, conditioned medium/co-culture experiments, IGFBP2 functional blocking, adipogenesis assays\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — single-cell identification combined with functional inhibition experiment, single lab, no mutagenesis\",\n      \"pmids\": [\"38729152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"In mice, Igfbp2 deficiency significantly impairs bariatric surgery-induced loss in adiposity and early improvement in insulin sensitivity (but not long-term glucose homeostasis), demonstrating that circulating IGFBP2 plays a causal role in the early metabolic improvements of bariatric surgery.\",\n      \"method\": \"Igfbp2 knockout mice, RYGB/BPD-DS/SG bariatric surgery models, insulin tolerance tests, adiposity measurements\",\n      \"journal\": \"Cell reports. Medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic loss-of-function (KO) with defined metabolic phenotype in surgical model, single lab\",\n      \"pmids\": [\"33948578\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"IGFBP2 stabilizes cytoplasmic β-catenin (via TRIM33 induction that depletes nuclear β-catenin) and cytoplasmic β-catenin then binds the 3'UTR of Oct4 RNA, regulating Oct4 transcript levels and promoting stemness in glioma cells. IGFBP2 overexpression/treatment induces TRIM33, an E3 ubiquitin ligase that degrades nuclear β-catenin.\",\n      \"method\": \"IGFBP2 overexpression/treatment, shRNA knockdown of TRIM33/β-catenin, RNA immunoprecipitation (RNAIP) for β-catenin/Oct4 RNA interaction, luciferase reporter, nuclear/cytoplasmic fractionation, neurosphere assay\",\n      \"journal\": \"Journal of neuro-oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNAIP and reporter assay establish cytoplasmic β-catenin/Oct4 mRNA interaction, fractionation confirms compartment, single lab\",\n      \"pmids\": [\"32803659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"IGFBP2 overexpression in developing chick long bones inhibits IGF-I- and IGF-II-mediated chondrocyte proliferation and matrix synthesis in vitro and in vivo, establishing IGFBP2 as an inhibitor of IGF action in skeletal development. IGFBP2 excess shortens long bones by inhibiting chondrocyte proliferation without affecting chondrocyte maturation markers.\",\n      \"method\": \"RCAS retroviral IGFBP2 overexpression in chick wing skeletal elements, in vitro chondrocyte proliferation/matrix synthesis assays with IGF-I, IGF-II, and long-R3-IGF-I (IGFBP-resistant analog)\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — in vivo overexpression model combined with in vitro mechanism dissection using IGFBP-resistant IGF analog, multiple orthogonal methods\",\n      \"pmids\": [\"16183342\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"IGFBP2 upregulates DNA-PKcs expression in astrocytoma cells in a time- and dose-dependent manner following exogenous IGFBP2 stimulation. IGF-1 had no effect on DNA-PKcs induction, suggesting an IGF-1-independent mechanism for IGFBP2-driven DNA repair.\",\n      \"method\": \"Exogenous IGFBP2 stimulation of astrocytoma cells, time- and dose-response western blot for DNA-PKcs, comparison with IGF-1 treatment\",\n      \"journal\": \"Journal of child neurology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single-method protein induction assay, no mechanistic dissection of pathway, single lab\",\n      \"pmids\": [\"18952587\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SARM1 in neurons promotes neuroinflammation and demyelination in experimental autoimmune encephalomyelitis by upregulating IGFBP2, which activates NF-κB signaling. SARM1 knockout reduced neuronal IGFBP2 levels; restoring NF-κB activation in SARM1 knockout EAE mice partially reversed the protective phenotype.\",\n      \"method\": \"SARM1 conditional KO in CNS (Nestin-CKO), RNA-seq, RT-PCR, immunostaining, NF-κB activation assay, NF-κB activator rescue experiment in SARM1-KO mice\",\n      \"journal\": \"Acta physiologica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis (KO plus NF-κB rescue) with pathway confirmation, single lab\",\n      \"pmids\": [\"37186158\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"HIF-1α transcriptionally drives IGFBP2 expression in Wilms tumor, and IGFBP2 in turn supports constitutive IGF1-AKT signaling. Deficiency of either HIF-1α or IGFBP2 significantly impaired tumor growth and nearly abrogated metastasis in xenograft models; pharmacologic HIF-1α inhibition (echinomycin nanoliposomes) suppressed the HIF-1α-IGFBP2 axis.\",\n      \"method\": \"HIF-1α and IGFBP2 shRNA knockdown in xenografted Wilms tumor, patient-derived xenograft models, echinomycin nanoliposome treatment, AKT phosphorylation assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis (HIF-1α KD → IGFBP2 → AKT) with pharmacologic confirmation in PDX model, single lab\",\n      \"pmids\": [\"34155347\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"IGFBP2 is a secreted and intracellular pleiotropic protein that (1) binds and sequesters IGF-I and IGF-II via its IGF-binding domain, modulating their availability and downstream IGF receptor signaling; (2) interacts with integrin α5 (and β1) via its C-terminal RGD motif to activate FAK/ERK/PI3K-AKT pathways, promoting cell migration, invasion, and survival while reducing PTEN; (3) translocates to the nucleus where it potentiates EGFR nuclear accumulation and EGFR/STAT3 transcriptional activation of target genes including VEGF and PD-L1; (4) activates NF-κB (p65 nuclear translocation) via PI3K/Akt/IKKβ to drive EMT and metastasis; (5) stimulates osteoblast differentiation through its heparin-binding domain-1 interacting with RPTPβ to activate AKT; (6) stabilizes cytoplasmic p21 to inhibit apoptosis; (7) acts as a leptin-regulated hepatokine that improves hepatic insulin sensitivity in vivo; and (8) in the brain, enhances NMDA receptor-dependent LTP and excitatory synaptic transmission, with IGF1R-independent mechanisms mediating neuroplasticity effects.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"IGFBP2 is a secreted and intracellular pleiotropic protein that governs IGF availability and engages cell-surface and nuclear signaling to control cell migration, survival, differentiation, and metabolism [#0, #26, #32]. Its canonical extracellular role is to bind and sequester IGF-II: adipocyte-derived IGFBP2 limits IGF-II autocrine signaling to suppress breast cancer invasion [#26], and IGFBP2 excess inhibits IGF-I/IGF-II-driven chondrocyte proliferation during skeletal development [#32]; the IGFBP2-IGF-II complex is cleaved by MMP-9 to liberate active IGF-II [#6]. Beyond ligand sequestration, IGFBP2 acts as a signaling ligand through an RGD motif (D306) that binds integrin α5/β1, driving FAK/ERK and PI3K/Akt activation to promote migration, vasculogenic mimicry via SP1/CD144, survival through PTEN reduction, and—on podocytes—FAK-dependent mitochondrial injury and apoptosis [#0, #5, #9, #27]. A separate heparin-binding domain (HBD-1) engages RPTPβ to activate AKT and stimulate osteoblast differentiation [#1]. IGFBP2 also translocates to the nucleus, where it potentiates EGFR nuclear accumulation and EGFR/STAT3 transactivation of targets including VEGF and PD-L1, and where it activates NF-κB (p65) through PI3K/Akt/IKKβ to drive ZEB1-dependent epithelial-mesenchymal transition and metastasis [#2, #3, #13, #14, #15]. Through STAT3-driven IL-10, IGFBP2 also reshapes the tumor immune microenvironment toward M2 macrophage polarization [#8]. In metabolism, IGFBP2 is a leptin-regulated hepatokine that improves hepatic insulin sensitivity and reverses hyperglycemia in vivo [#16], and in the CNS it enhances NMDA receptor-dependent excitatory transmission, LTP, and structural plasticity through IGF1R-independent mechanisms [#23, #24, #25]. Its expression is controlled by p16(INK4a), HIF-1α, promoter histone acetylation, and intronic CpG methylation [#18, #35, #21, #17].\",\n  \"teleology\": [\n    {\n      \"year\": 2006,\n      \"claim\": \"Established that IGFBP2 acts not merely as an IGF carrier but as an integrin ligand, defining the RGD motif as the structural basis for a direct cell-motility-promoting interaction.\",\n      \"evidence\": \"Co-IP, RGD-to-RGE (D306E) mutagenesis, integrin α5 siRNA, and migration assays\",\n      \"pmids\": [\"16569642\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve downstream kinase cascade from integrin engagement\", \"Did not address β1 subunit contribution\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Showed that proteolysis of the IGFBP2-IGF-II complex by MMP-9 controls bioavailable IGF-II, connecting matrix remodeling to IGF release and tumor cell motility.\",\n      \"evidence\": \"In vitro proteolysis with recombinant MMPs (negative controls MMP-2, MT1-MMP) and motility/growth assays\",\n      \"pmids\": [\"18563800\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cleavage sites not mapped\", \"In vivo relevance of MMP-9 cleavage not established\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defined IGFBP2 as a leptin-regulated metabolic hepatokine, answering whether IGFBP2 has a systemic glucose-regulatory function distinct from IGF sequestration.\",\n      \"evidence\": \"Adenoviral IGFBP2 overexpression across multiple diabetic mouse models with hyperinsulinemic-euglycemic clamp\",\n      \"pmids\": [\"20074524\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular receptor/effector for hepatic insulin sensitization not identified\", \"Direct hepatocyte target undefined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Demonstrated that intracellular/nuclear IGFBP2 has a transcriptional function, transactivating the VEGF promoter and driving angiogenesis.\",\n      \"evidence\": \"VEGF promoter luciferase reporter, cell fractionation, immunofluorescence, and chick CAM xenograft\",\n      \"pmids\": [\"21750048\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"DNA-binding partner mediating promoter activation not identified\", \"Single lab, no structural validation\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identified a second receptor system—HBD-1 binding RPTPβ to activate AKT—explaining how IGFBP2 promotes osteoblast differentiation independently of the integrin/RGD axis.\",\n      \"evidence\": \"RPTPβ Co-IP, HBD-1 mutagenesis, IGFBP2-null osteoblast rescue, synthetic peptide rescue\",\n      \"pmids\": [\"24839202\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of HBD-1/RPTPβ interaction unresolved\", \"How RPTPβ engagement activates AKT not detailed\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Linked nuclear IGFBP2 to oncogenic receptor signaling by showing it potentiates EGFR nuclear accumulation and EGFR/STAT3 transactivation to drive glioblastoma invasion.\",\n      \"evidence\": \"Overexpression/exogenous treatment, nuclear fractionation, STAT3 reporter, invasion assays\",\n      \"pmids\": [\"25893308\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct IGFBP2-EGFR binding mode not defined\", \"Mechanism of EGFR nuclear import unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined a PI3K/Akt/IKKβ-NF-κB(p65) cascade by which IGFBP2 drives EMT, with PTEN as an opposing brake.\",\n      \"evidence\": \"Overexpression/knockdown, p65 fractionation, pathway inhibitors, PTEN rescue epistasis, in vivo metastasis\",\n      \"pmids\": [\"27659045\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Upstream receptor coupling IGFBP2 to PI3K not specified here\", \"Single lab\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showed the integrin-FAK/ERK axis feeds SP1-driven CD144 transcription to enable vasculogenic mimicry, and that NLS-dependent nuclear p65 translocation drives ZEB1-mediated EMT and metastasis.\",\n      \"evidence\": \"Co-IP (α5/β1), ChIP (SP1-CD144), reporter assays, NLS mutagenesis, orthotopic and xenograft models\",\n      \"pmids\": [\"30368528\", \"29885520\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Crosstalk between cytoplasmic integrin signaling and nuclear NF-κB function not unified\", \"ZEB1 promoter occupancy by p65 mapped only in part\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Extended nuclear EGFR signaling to immune evasion (PD-L1 via EGFR/STAT3) and immunosuppression (STAT3/IL-10-driven M2 macrophage polarization and Treg infiltration), and established CNS roles in neuronal excitability and synaptic potentiation.\",\n      \"evidence\": \"Knockdown with PD-L1/STAT3 readouts and xenografts; macrophage polarization with PDAC model; astrocytic P2Y1R overexpression with Ca2+ imaging; igfbp2-KO electrophysiology with rescue\",\n      \"pmids\": [\"32120023\", \"33309859\", \"39117630\", \"31832311\", \"31818638\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor mediating CNS excitability effects of IGFBP2 not defined\", \"Whether nuclear and immune mechanisms operate in the same cells unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified intracellular protein-stabilization roles—protecting cytoplasmic p21 from ubiquitination to block apoptosis, and stabilizing cytoplasmic β-catenin via TRIM33 to regulate Oct4 and stemness.\",\n      \"evidence\": \"Co-IP and ubiquitination assays in keratinocytes; RNAIP, fractionation, and neurosphere assays in glioma\",\n      \"pmids\": [\"32302288\", \"32803659\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct binding interfaces (IGFBP2-p21) not mapped\", \"How a secreted protein accesses cytoplasmic substrates not resolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Mechanistically dissected the neuroplasticity activity using an IGFBP2-mimetic peptide, showing NMDA receptor- and IGF2R-dependent (IGF1R-independent) synaptic remodeling and rescue of Shank3 deficits.\",\n      \"evidence\": \"Peptide binding, IGF1R antagonism, phosphoproteomics, electrophysiology, behavior in Shank3+/- mice\",\n      \"pmids\": [\"36481930\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The functional receptor on dendrites not definitively identified\", \"Endogenous full-length IGFBP2 vs mimetic peptide equivalence not established\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Showed context-dependent IGF-sequestration outcomes: adipocyte IGFBP2 restrains tumor invasion by binding cancer-derived IGF-II, while podocyte integrin α5/FAK signaling makes IGFBP2 pro-apoptotic in diabetic kidney disease.\",\n      \"evidence\": \"Patient-derived adipocyte CM with IGF-II siRNA/neutralizing antibody and invasion assays; ITGA5 knockdown and FAK inhibition with mitochondrial/apoptosis readouts and STZ-DKD model\",\n      \"pmids\": [\"37436978\", \"38796567\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants of pro- vs anti-tumor IGFBP2 output not unified\", \"Tissue factors switching IGFBP2 between sequestration and signaling unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How IGFBP2 partitions among its mutually exclusive activities—extracellular IGF sequestration, integrin/RPTPβ signaling, and nuclear transcriptional functions—within a given cell, and what controls its nuclear import and access to cytoplasmic substrates, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model unifying ligand-binding, RGD, HBD-1, and NLS functions\", \"Mechanism of nuclear translocation undefined\", \"Receptor for IGF1R-independent CNS effects not identified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140313\", \"supporting_discovery_ids\": [26, 6, 32]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 9]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [3, 2, 14]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [16, 26, 29]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [3, 2, 14]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [12, 31]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 5, 27]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [16, 30]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [4, 14, 35]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [23, 25, 22]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"ITGA5\",\n      \"ITGB1\",\n      \"PTPRB\",\n      \"EGFR\",\n      \"IGF2\",\n      \"CDKN1A\",\n      \"CTNNB1\",\n      \"DNAPK\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}